Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Diarrhea 3Prostatic Neoplasms 2Neoplasms 2Breast Neoplasms 2Vipoma 1Somatostatinoma 1Serotonin Syndrome 1Recurrence 1Rectal Neoplasms 1Pheochromocytoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphocele 1Intestinal Obstruction 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1Adenoma 1Acromegaly 1

Interventions

Fluorouracil 25Oxaliplatin 24Irinotecan 24Leucovorin 23Bevacizumab 23Capecitabine 18Cetuximab 15Radiotherapy 6Gene Expression Profiling 5regorafenib 4Immunohistochemistry 4Gemcitabine 4Folfox protocol 4Colonoscopy 4Cisplatin 4Celecoxib 4Amplified Fragment Length Polymorphism Analysis 4Reverse Transcriptase Polymerase Chain Reaction 3Receptor Protein-Tyrosine Kinases 3Polymerase Chain Reaction 3Nivolumab 3Mitomycin 3Doxorubicin 3Cyclophosphamide 3Cholecalciferol 3Biopsy 3Aspirin 3sargramostim 2pembrolizumab 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Colonic Neoplasms × Octreotide × Clear all
NCT00006269 2012-05-25

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Novartis

Phase 3 Terminated
89 enrolled
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡